Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toludivenlafaxine PET Occupancy Study
NCT05905120Phase 1Completed
- Sponsor
- Shanghai Mental Health Center
- Start
- Mar 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of toludesvenlafaxine in major depressive disorder (MDD), sponsored by Shanghai Mental Health Center. Primary endpoint: Percentage of Dopamine Transporters Occupancy in the Basal Ganglia at Day 4. Started Mar 2023; status: completed.
02
Drugs
toludesvenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05905120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05905120.